Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha9/9/2026Neutral
SPTX
Seaport Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.15B
P/E Ratio
—
EPS
$-2.52
Beta
—
52W High
$28.38
52W Low
$0.01
50-Day MA
$22.75
200-Day MA
$20.42
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc. (SPTX) is a pioneering biopharmaceutical firm dedicated to advancing cutting-edge immune-oncology therapies to meet critical unmet medical needs, particularly in the field of oncology. The company leverages innovative technologies and a robust research pipeline to develop targeted treatment solutions for complex diseases, with a strong focus on cancer. Supported by strategic collaborations and an experienced management team, Seaport Therapeutics is well-positioned to drive scientific advancements that enhance patient outcomes and reshape the landscape of cancer treatment and immunotherapy.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-143.75M |
| Operating Margin | 0.00% |
| Return on Equity | -28.10% |
| Return on Assets | -18.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.89 |
| Price-to-Book | 2.70 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $53.53M |
| Float | $18.43M |
| % Insiders | 35.14% |
| % Institutions | 70.72% |
Historical Volatility
HV 10-Day
67.64%
HV 20-Day
75.46%
HV 30-Day
74.41%
HV 60-Day
72.90%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($38.29 target)
1
Strong Buy5
Buy1
HoldLatest News
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers.
Business Wire9/9/2026Neutral
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers.
Business Wire9/9/2026Neutral
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.
Business Wire8/3/2026Neutral
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™.
Business Wire6/9/2026Neutral
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to participate in two upcoming investor conferences.
Business Wire6/1/2026Neutral
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9 million. In London, PureTech shareholders saw the share price climb 9.56% to 139.8p.
Proactive Investors5/1/2026Positive
Seaport Therapeutics raises about $255 million in upsized IPO
Drug developer Seaport Therapeutics said on Thursday it had raised about $255 million in its upsized initial public offering in the United States.
Reuters5/1/2026Positive
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering.
Business Wire5/1/2026Neutral
Drug developer Seaport Therapeutics targets $912 million valuation in US IPO
Drug developer Seaport Therapeutics said on Monday it was aiming for a valuation of $912 million in its initial public offering in the United States.
Reuters4/27/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SPTX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/28/2026